Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. - Wikidata - awgldk - TriplyDB

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.

http://www.wikidata.org/entity/Q42999474

about

Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C KASL clinical practice guidelines: management of hepatitis C GAMMA GLUTAMYLTRANSFERASE IMPACT IN THERAPEUTIC RESPONSE OF CHRONIC HEPATITIS C: a systematic review of the literature Hepatitis C virus: A global view Response Prediction and Treatment Tailoring for Chronic Hepatitis C Virus Genotype 1 Infection Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to Therapy Rapid and early virological response to chronic hepatitis C treatment with IFN 2b or PEG-IFN 2b plus ribavirin in HIV/HCV co-infected patients Abbott RealTime Hepatitis C Virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV Assays for Prediction of Sustained Virological Response to Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients Performance of the Abbott Real-Time PCR Assay Using m2000sp and m2000rt for Hepatitis C Virus RNA Quantification Extended-therapy duration for chronic hepatitis C, genotype 1: The long and the short of it Expert opinion on the treatment of patients with chronic hepatitis C On-treatment predictions of success in peg-interferon/ribavirin treatment using a novel formula Immediate virological response predicts the success of short-term peg-interferon monotherapy for chronic hepatitis C Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study Diagnosis, management, and treatment of hepatitis C: an update Current challenges in viral hepatitis, antimicrobial resistance and the influenza pandemic.Challenges in the treatment of HIV and HCV coinfection.Persistence of hepatitis C RNA in liver allografts is associated with histologic progression independent of serologic viral clearance.Individualisation of antiviral therapy for chronic hepatitis C.Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment Identification of treatment efficacy-related host factors in chronic hepatitis C by ProteinChip serum analysis Optimizing the dose and duration of therapy for chronic hepatitis C.Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response Prediction of effect of pegylated interferon alpha-2b plus ribavirin combination therapy in patients with chronic hepatitis C infection.Evidence for separation of HCV subtype 1a into two distinct clades.Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C.Evolution of interferon-based therapy for chronic hepatitis C.Predicting the probable outcome of treatment in HCV patients.A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors.Peginterferon and ribavirin treatment for hepatitis C virus infection U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin for "difficult-to-treat" HCV genotype 1 patients.Interferon in the treatment of chronic hepatitis C: a drug caught between past and future.Hepatitis C virus virology and new treatment targets.The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection.Cost-effectiveness of screening for hepatitis C in Canada.An extended treatment protocol with pegylated interferon and ribavirin for hepatitis C recurrence after liver transplantation HBV and HCV therapy.Optimal duration of treatment for HCV genotype 1 infection in slow responders: a meta-analysis.

P2860

Q24200534-8BF32781-57DE-41CD-8768-BFC86A4F90F9 Q24201588-F2FCA07E-FDFC-4B0F-AFC2-8B6C50226D1D Q26752471-4231F8DC-24C9-4C4B-8888-E26E3003BD87 Q26781202-4A172DFA-24D4-454D-8FAD-E3F27F991CA7 Q26862531-C9DF9D05-12E8-43FC-B06E-39FCF24D0330 Q27481003-CF6570F1-A267-4ACB-AE12-43F8C68AFDB3 Q27481007-0A3B7B50-7699-46A7-9A68-A99131FF2580 Q27481046-70EBF55A-B3E1-447F-A4EE-BC3424E09299 Q27487942-D1C99F57-215F-48B1-99EF-7F5C399DF68A Q27488563-C89302A3-1053-4614-BCEA-29D9A16D9838 Q27489046-FF235199-8C33-42EB-AD6E-886475780D5C Q27489903-39222E16-DF6A-44D7-A024-8CFEF1E191F6 Q27490760-12DF626C-B35B-4798-9C03-7C2DE2FF3DFF Q27491312-DE78420B-9644-4861-996A-10E0EC70711E Q28546936-291267B0-465F-4AAF-87E3-AD5EE1224AF3 Q29619682-0AD0D18D-D1E5-4DF7-822E-B298580DB344 Q30381336-E3B3B76B-F8FE-4A97-9A13-2AAC5B632846 Q30389282-EB511FAC-F8AD-47DE-A8E8-F2C4449E1AA0 Q30437276-43E63998-131B-4AB0-876E-D46176CD36D0 Q33390478-470217E8-85D1-4FB2-A0F2-50A4E6C5501D Q33557770-B65AB9C5-35D4-4AB3-ADBC-08E7E3AE22F1 Q33712188-D860DAD3-E0BF-49A1-A734-E884012DDE03 Q33855483-AECB9BD2-79A3-4810-9A40-50D9283081BF Q33956478-4A7FED54-9E20-45F0-B3C1-192241C85EA7 Q34098886-76682C13-2DEB-48CD-9AA2-3D85418B4E2D Q34242504-D32087D1-F48B-4392-89B2-022BB18C6925 Q34334776-25957D9F-CA03-4472-925E-647B95488F0F Q34342092-16AB4D9D-EB03-475A-839A-7E3DA76DFA49 Q34409039-37BBD0C9-4BFE-41A0-800D-AB787890E0AC Q34513827-C66D6F2A-4BEA-4576-9EC7-F01F3ED1B6DA Q34521371-FE93D810-F3F7-4810-BED2-6FC7D1C38652 Q34587019-81CBF56C-C51A-4B53-AA65-6AFFB6B46310 Q34626479-902DE2EA-47C9-4B6F-BD4B-EC31571776E4 Q34974042-956BF20A-48AE-46A3-A431-0D23823894AF Q34996746-3BD7F301-2BE5-403A-AEF6-92E4DB96C4F7 Q35037574-F93D9B72-C3A7-4E09-8011-836ED0072886 Q35088460-CDB07659-BA35-4D12-A7DE-6307BC2BE398 Q35173005-C77FD8F2-DBBB-4D6D-B0F3-57062A35F789 Q35259824-486F043B-0A0A-4773-952D-EE211561C495 Q35582452-88B22A44-E4AC-4E01-B2FD-27DEF9DE7E2B

P2860

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.

http://www.wikidata.org/entity/Q42999474

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Extended treatment duration fo ...... rferon-alfa-2a plus ribavirin.

@en

Extended treatment duration fo ...... rferon-alfa-2a plus ribavirin.

@nl

type

label

Extended treatment duration fo ...... rferon-alfa-2a plus ribavirin.

@en

Extended treatment duration fo ...... rferon-alfa-2a plus ribavirin.

@nl

prefLabel

Extended treatment duration fo ...... rferon-alfa-2a plus ribavirin.

@en

Extended treatment duration fo ...... rferon-alfa-2a plus ribavirin.

@nl

P1433

Q42999474-57FE2E30-CE44-40D1-80DA-C1D32FAC4C93

P1476

Q42999474-5F5A8881-E50B-4474-AF04-E86C67678B7D

P2093

Q42999474-046EE6C6-A488-45B3-9F7C-193E68EB6190

Q42999474-2B6E375D-C109-4352-8A1E-C5A34D031D01

Q42999474-304865A9-C468-406D-9EBB-5A6EF21C0238

Q42999474-33846FAE-AE98-4453-920A-DA3C764165A7

Q42999474-35BDF2D9-84DA-4649-9CC5-D3F3FABF3522

Q42999474-4256B3F9-F2BD-42B5-9A0D-59EDF315605C

Q42999474-71D7EC05-A081-4839-AF5B-8852BA574ACF

Q42999474-89D6E38B-C65C-4CAF-8410-2B2CB0700300

Q42999474-8CAEB522-B2DC-44F1-A709-736A12991421

Q42999474-A2F3974F-7889-4B69-989C-5B43F53EDB81

P304

Q42999474-AD2A929E-C0B7-4BA0-B622-BD4575E7B788

P31

Q42999474-74F3D3E2-F1F9-4F19-BC06-16093D8C8D1D

P356

Q42999474-E066E426-99B3-46DA-A0CE-EC3C1EAB5529

P407

Q42999474-9FB92993-6088-40EC-A653-7ACAE6990AE2

P433

Q42999474-BD2B0578-0FE0-4607-BA02-05E8007AB9F5

P478

Q42999474-FFDE4B35-109F-470A-A010-17144A28C0DF

P50

Q42999474-5ACD44A8-C10A-4D51-BEBC-4498B722E5B6

Q42999474-624A7B60-1D2F-4F22-A246-35E2700FE9B5

Q42999474-D2DAE773-9FE9-4C44-B104-6A29C4701084

P577

Q42999474-5845D34E-CF50-4C11-BFE6-389F65239164

P698

Q42999474-692DB4DA-35AF-45BF-AA29-7AFB115C850E

P356

J.GASTRO.2006.02.015

P1433

Gastroenterology

P1476

Extended treatment duration fo ...... rferon-alfa-2a plus ribavirin.

@en

P2093

Birgit Kallinowski

http://www.w3.org/2001/XMLSchema#string

Christoph Sarrazin

http://www.w3.org/2001/XMLSchema#string

Gerd R Pape

http://www.w3.org/2001/XMLSchema#string

Hartwig Klinker

http://www.w3.org/2001/XMLSchema#string

Jens Rasenack

http://www.w3.org/2001/XMLSchema#string

Michael von Wagner

http://www.w3.org/2001/XMLSchema#string

Peter Buggisch

http://www.w3.org/2001/XMLSchema#string

Peter Martus

http://www.w3.org/2001/XMLSchema#string

Samer Nasser

http://www.w3.org/2001/XMLSchema#string

Tilman Gerlach

http://www.w3.org/2001/XMLSchema#string

P304

1086-1097

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.GASTRO.2006.02.015

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

130

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16618403

http://www.w3.org/2001/XMLSchema#string